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ABSTRACT 
Background: Chronic lung allograft dysfunction (CLAD) hampers long-term survival after lung 
transplantation. Common fibrosis-related mechanisms in idiopathic pulmonary fibrosis and CLAD, 
instigated the consideration of investigating the differential regulation of pleural mesothelium and TGF-
β1 in restrictive allograft syndrome (RAS). 
Methods: TGF-β1 was assessed in broncho-alveolar lavage (BAL) using ELISA and via immune 
staining of explant biopsies. To assess the role of the pleura, explanted BOS and RAS lungs were 
compared using CT scans, calretinin stainings, western blot and qRT-PCR. Lastly, a pleural mesothelial 
cell line was used to assess mesothelial-to-mesenchymal transition and its inhibition.  
Results: TGF-β1 was increased in BAL of RAS patients (p=0.035), and was present in the (sub)pleural 
area of biopsies. Explanted RAS lungs demonstrated an increased volume fraction of pleura (p=0.0004), 
a higher proportion of calretinin-positive stainings (p=0.0032), and decreased E-cadherin (p=0.019) and 
increased α-SMA (p=0.0089) mRNA expression and protein levels in isolated pleural tissue. Moreover, 
TGF-β1 stimulation of pleural mesothelial cells led to a phenotypical switch to mesenchymal cells, 
accompanied with an increased migratory capacity. IL-1α was able to accentuate TGF-β1-induced 
mesothelial-to-mesenchymal transition. None of the tested drugs could inhibit mesothelial-to-
mesenchymal transition at the used concentrations.  
Conclusion: Our results support an interplay between TGF-β1 and the pleural mesothelium in the 
pathophysiology of restrictive allograft syndrome.  
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INTRODUCTION 
Chronic lung allograft dysfunction (CLAD) continues to impair long-term survival after lung 
transplantation (LTx), which has the lowest survival rates of all solid organ transplants 1. Nowadays, 
chronic rejection is considered a heterogeneous entity with at least two clinical phenotypes: bronchiolitis 
obliterans syndrome (BOS) and restrictive allograft syndrome (RAS). BOS is characterized by an 
obstructive pulmonary function defect, obliterative bronchiolitis (OB) on histopathology, and mostly air 
trapping on chest CT, while RAS is characterized by a restrictive pulmonary function defect 
accompanied by (sub)pleural thickening, persistent pleuroparenchymal infiltrates and fibrosis on chest 
CT 2. Moreover, patients suffering from RAS have a worse prognosis (1-1.5 years) compared to patients 
with BOS (3-5 years) 3–5.  
In RAS, fibrosis formation occurs in a pleuroparenchymal pattern 6 and although the exact nature of 
this fibrotic process has not been elucidated yet, parallels with idiopathic pulmonary fibrosis (IPF) have 
been suggested, evidenced by similar immune activation, increased production and deposition of 
extracellular matrix, and proliferation of fibroblasts, however there are not many comprehensive studies 
to compare the similarities and differences between IPF and RAS 7. Recently, the pleural mesothelium 
was implicated as a potential source of (myo-)fibroblasts in IPF 8. The pleura is a metabolically active 
membrane of fibrous tissue that lines the interior of the thoracic cavity and consists of two layers: the 
parietal layer lines the thoracic wall and the visceral layer is attached to the lung parenchyma 9. Apart 
from facilitating movement of the lung, pleural mesothelial cells (PMCs) also respond to injury by 
proliferating and producing pro-inflammatory and extracellular matrix proteins 10,11. During embryonic 
development, mesothelial cells migrate into lung parenchyma to form smooth muscle cells and (myo-) 
fibroblasts. Re-activation of this developmental pathway, during which PMCs differentiate into (myo-) 
fibroblasts after stimulation with TGF-β via a process called mesothelial-to-mesenchymal transition 
(MMT), is suggested to play a role in the pathogenesis of IPF and to actively contribute to fibrosis 
formation 8,12.   
TGF-β is considered a key player in chronic fibrotic lung disorders and is responsible for recruitment 
of circulating fibrocytes and inflammatory cells, inducing a pro-fibrotic environment and activating 
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collagen 13. Moreover, gene expression profiling of transbronchial biopsies implicated the TGF-β axis 
in CLAD 14. 
In the present study, we investigated the role of TGF-β1-induced transformation of PMCs into (myo-) 
fibroblasts in RAS. 
 
 
MATERIALS & METHODS  (Additional information in online supplement) 
Study design & population 
In this cross-sectional study, patient inclusion was based on retrospective diagnosis of BOS and RAS 
via a combination of spirometry, CT and availability of samples (supplementary method 1). When 
patients changed CLAD phenotype during their disease course 4, the last phenotype prior to redo-
transplantation or death was used for analysis. The Leuven University Hospital Ethics Committee 
(S57742) and the local biobank board (S51577) approved the study and all patients provided written 
informed consent that collected material could be used for research. 
Specimen collection & processing 
Depending on availability, different specimens were obtained from different patients (figure S1). 
Broncho-alveolar lavage & TGF-β1 measurement 
Broncho-alveolar lavage (BAL) was performed as described previously, using 2x50 cc of saline 15. 
TGF-β1 was measured in BAL supernatant of BOS (n=23) and RAS (n=26) patients at CLAD diagnosis 
using sandwich ELISA (R&D Systems, Abingdon, UK) according to manufacturer’s instructions. As a 
control group, BAL of stable (never CLAD) lung transplant patients (n=20) were used. 
Patient blood samples and mesothelin measurement 
Mesothelin protein levels were measured in serum of BOS (n=26) and RAS (n=27) patients using 
sandwich ELISA (R&D Systems) according to manufacturer’s instructions. As a control group, serum 
samples of stable (never CLAD) lung transplant patients (n=22) were used. 
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Explant lungs & CT analysis 
Explanted lung specimens were collected from BOS (n=8) and RAS (n=8) patients undergoing redo-
transplantation and processed as described previously 16. Unused donor lungs (n=7) served as controls 
and were obtained under existing Belgian law. CT images were processed using Mimics® software 
(Materialise NV, Leuven, Belgium) and resulting segmentations enabled calculation of the volume 
fraction of pleura and attached infiltrates relative to the total lung volume. 
Lung biopsies & immunohistochemistry for calretinin and TGF-β1 
Lung biopsies were obtained during redo-transplantation, VATS-biopsy or autopsy of patients with 
BOS (n=19) and RAS (n=19). Non-transplant control biopsies (n=14) were obtained during autopsy of 
patients without underlying lung disease (n=11) or during resection of non-diseased lung tissue from 
lung carcinoma patients with normal spirometry (n=3). All biopsies were retrieved at random by the 
Hospitals Pathology Department for routine clinical purposes and not specifically for this study. Paraffin 
sections were prepared from each biopsy and stained with calretinin (Dako, Agilent, Heverlee, Belgium) 
and/or TGF-β1 (Atlas, Bromma, Sweden) antibody (supplementary method 2 & 3). Control stainings for 
TGF-β1 were performed on liver and tonsil biopsies. 
Multiplex immunofluorescent staining for immune subsets 
After deparaffinization and heat-induced antigen retrieval, quadruple staining with CD4, CD8, CD20 
and CD68 (table S2, supplementary method 4) was performed via automated multiplex 
immunofluorescence using the Ventana Benchmark Discovery (Ventana Medical Systems Inc., AZ, 
USA). 
Protein analysis & quantitative real-time PCR analysis of MMT markers in pleural tissue 
Pleural tissue was isolated from frozen explanted lungs of BOS (n=5), RAS (n=6) and unused donors 
(n=6) and used for protein and total RNA extraction (supplementary method 5 & 6). Subsequently, 
western blot (supplementary method 9) and qRT-PCR of MMT markers was performed (table S3). To 
quantify the band intensity of the western blots, 1D (Totallab, Newcastle upon Tyne, UK) was used 
including background correction. For the qRT-PCR, a 260/280 ratio of at least 1.8 was ensured for all 
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RNA samples (table S4). Data analysis was carried out with Eco™ Real-Time PCR System (Illumina, 
USA) via the comparative cycle threshold (Ct) method. 
Pleural mesothelial cell culture 
Human pleural mesothelial cells (MeT-5A cells, ATCC, Molsheim, France) between passages two 
and twelve were used. Cells were either (i) stimulated with TGF-β1, IL-6, or IL-1α (10 µg/mL, Bioké, 
Cell Signaling Technology, Leiden, The Netherlands), (ii) treated with pirfenidone (5 mM; GenenTech, 
Michigan, USA), azithromycin (0.01 µM, Sigma-Aldrich, Bornem, Belgium), montelukast (1 µM, 
Cayman, Michigan, USA), or dexamethasone (5 µM, Sigma-Aldrich), or (iii) exposed to a combination 
of these agents for 48 hours prior to western blot analysis. Negative control cells were stimulated with 
an equivalent amount of vehicle. Migration was assessed using Ibidi® chamber migration assays 
(Culture-Insert 2 well µ-dishes, REF81176, Ibidi GmbH, Germany). Additional information can be 
found in supplementary methods 7-10. 
Statistical analysis 
All results are presented as mean ± standard error of mean or as median (interquartile range). Discrete 
data were compared with contingency tables. Comparing two continuous variables was done using 
Mann–Whitney U test; for multiple groups, one-way ANOVA with Tukey’s multiple comparisons test, 
Kruskal-Wallis test with Dunn’s post hoc test or the two-way ANOVA with Sidak’s multiple 
comparisons test was used. Survival analysis was performed using Log-rank test. GraphPad prism 6.0 
software (San Diego, CA, USA) was used for statistical analysis. P<0.05 was considered significant. 
 
 
RESULTS 
Patient characteristics and distribution of sample types among the cohort are shown in table S1 and 
figure S1. 
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Importance of TGF-β1 in RAS patients 
At diagnosis, RAS patients had higher TGF-β1 levels in BAL compared to stable patients (p=0.02, 
figure 1A). Based on the concentrations of TGF-β1 in RAS, the median level (14.5 pg/mL) was defined 
as a threshold to stratify RAS patients. RAS patients with high TGF-β1 levels demonstrated a worse 
post-diagnosis graft survival compared to RAS patients with low TGF-β1 levels (p=0.033, HR 2.77, 95% 
CI 1.1-7.1, figure 1B).  
Immunohistochemical stainings of TGF-β1 on lung biopsies from RAS patients demonstrated three 
different patterns: (i) relatively low TGF-β1 expression, with primarily subpleural staining and TGF-β1 
positivity in stromal cells and macrophages (21%; figure 2A-C); (ii) intermediate TGF-β1 expression 
with subpleural and intra-alveolar staining (47%; figure 2D); and (iii) diffuse staining of the extracellular 
matrix, particularly in biopsies with advanced fibrosis (32%; figure 2E). 
 Lymphocyte subpopulations in the three TGF-β1 patterns were investigated by multiplex 
immunofluorescence for CD4 (T helper cells), CD8 (cytotoxic T cells), CD20 (B cells) and CD68 
(macrophages). In the low TGF-β1 group (figure 3A), there was a low degree of inflammation, with little 
and dispersed CD4, CD20 and CD68 positive staining. In the intermediate TGF-β1 group (figure 3B), 
there was a low number of CD4, CD8, CD20 and CD68 positive cells. In the high TGF-β1 group (figure 
3C and S2), there was abundant CD4, CD8, CD20 and CD68 positive cells. 
Pleural volume is increased in RAS 
Analysis of CT scans of inflated, explanted lungs showed an increased volume percentage of pleura 
and attached infiltrates in RAS lungs (p=0.0004, figure 4) compared to non-transplant controls 
(p=0.025) and BOS (p=0.0003). No differences were observed between non-transplant controls and 
BOS (p>0.05). 
 Increased pleural reactivity in RAS 
Given this increase in pleural volume, we sought to investigate the reactivity of the pleural 
mesothelial cells. First, the presence of PMCs within the lung was assessed using calretinin, a marker 
for reactive mesothelial cells. A bigger proportion of RAS biopsies showed positivity for calretinin 
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(53%, p=0.0001, figure 5A), compared to BOS (5%) and controls (0%). Calretinin-positive cells were 
found deeper within the parenchyma in RAS biopsies (figure 5B). To associate the previous TGF-β1 
staining patterns with calretinin positivity, biopsies of low and intermediate TGF-β1 expression were 
grouped together and compared to biopsies with high TGF-β1 expression. In the low or intermediate 
TGF-β1 biopsies, only 5 out of 13 (38%) were calretinin-positive, while in the high TGF-β1 biopsies 5 
out of 6 (83%) were calretinin-positive (figure 5C, p=0.069).  
Secondly, mesothelin protein levels were measured in serum, as mesothelin has been reported to be 
expressed in reactive mesothelial cells 17. Mesothelin levels were increased in RAS (p=0.0022, figure 6) 
and tended to be higher in BOS (p=0.055) compared to stable patients. 
Pleural tissue of RAS lungs shows evidence of MMT 
To further confirm reactivity of the pleura, pleural tissue was extracted from explanted lungs and 
MMT markers were assessed. At mRNA level, RAS pleura showed decreased expression of E-cadherin 
compared to controls (p=0.019, figure 7A) and a trend for lower expression compared to BOS (p=0.056). 
On the other hand, expression of α-SMA was increased in RAS compared to controls (p=0.0089, figure 
7C), but not compared to BOS (p=0.15). There were no differences in fibronectin (p=0.88, figure 7E) 
or Wilms’ tumor 1 (Wt1) (p=0.19, figure 7G) expression between groups. 
At protein level, RAS pleura showed decreased levels of E-cadherin compared to BOS (p=0.017) 
and a trend for lower levels compared to controls (p=0.054, figure 7B). On the other hand, α-SMA levels 
were increased in RAS compared to controls (p=0.015), but not compared to BOS (p=0.13, figure 7D). 
There were no differences in fibronectin (p=0.36, figure 7F). 
Exploration of possible triggers and treatments in a cell culture model 
To investigate the TGF-β1-pleural axis in more depth, an in vitro MMT model was used. MeT-5A 
cells stimulated with TGF-β1 (figure S3) showed (i) morphological changes (figure S5B), (ii) decreased 
E-cadherin (p<0.0001) and increased fibronectin levels (p<0.0001, figure S4), and (iii) increased 
migratory capacity (p=0.046, figure S5); evident of a mesothelial to mesenchymal phenotype change.  
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The ability of inflammation to influence the TGF-β1-pleural axis was assessed by exposing cells to 
IL-6 or IL-1α, two proteins that are upregulated in RAS 18. Stimulation with IL-6 or IL-1α alone (figure 
S3 and S6A-B) led to decreased E-cadherin levels (p=0.0011 and p=0.0022 respectively), but no change 
in fibronectin (p=0.24 for both IL-6 and IL-1α) compared to control cells. Cells exposed to TGF-β1 and 
IL-6 simultaneously (figure S6C) showed no differences in E-cadherin or fibronectin compared to TGF-
β1-stimulated cells (p=0.31 and p=0.95 respectively). Cells exposed to TGF-β1 and IL-1α simultaneously 
(figure S6D) showed decreased E-cadherin levels (p=0.041) and a trend towards increased fibronectin 
levels (p=0.064) compared to TGF-β1-stimulated cells, indicating that IL-1α-related inflammation could 
aggravate MMT. 
Lastly, we investigated if known therapeutic agents could inhibit MMT. However, there was no 
difference in E-cadherin or fibronectin levels in TGF-β1-stimulated cells treated with either pirfenidone, 
montelukast, azithromycin or dexamethasone at the used doses compared to TGF-β1-stimulated cells 
without treatment (all agents p>0.05, figure S7). 
 
 
DISCUSSION 
In the present study, we provide evidence for a role of the TGF-β1-pleural axis in RAS. We 
demonstrated that TGF-β1 was increased in RAS in both BAL and lung biopsies. Abundant TGF-β1 
expression was accompanied with inflammation. Moreover, the degree of pleural fibrosis and adjacent 
fibrotic parenchymal infiltrates and thereby also the proportion of affected lung tissue was quantified, 
showing that this was increased in RAS. This was also accompanied by a higher proportion of calretinin-
positive staining in the parenchyma, increased mesothelin in serum, and decreased E-cadherin and 
increased α-SMA mRNA and protein levels in isolated pleural tissue of RAS. TGF-β1 stimulation of a 
pleural mesothelial cell line demonstrated a transition into a mesenchymal cell phenotype and increased 
migratory capacity, which is aggravated by IL-1α. Finally, we investigated the effect of drugs 
(azithromycin, montelukast, pirfenidone and dexamethasone) in ameliorating the change in E-cadherin 
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and fibronectin expression in cells. However, we were unable to demonstrate any convincing signal for 
benefit. 
TGF-β1 is an important pro-fibrotic mediator, playing key roles in chronic respiratory diseases 19. 
Within LTx, TGF-β1 is shown to induce epithelial-to-mesenchymal transition (EMT) and the production 
and secretion of matrix metalloproteinases in bronchial epithelial cells, while smaller studies directly 
implicated TGF-β1 with chronic rejection 20,21. Our results support the hypothesis of an important role 
for TGF-β1, especially in RAS via MMT. 
Mesothelial-to-mesenchymal transition (MMT) is very reminiscent of EMT, which has been 
implicated in the pathophysiology of OB 22. Several biomarkers can be used to demonstrate this 
mesenchymal transitioning of cells 23. We showed a decrease of E-cadherin in protein and mRNA in 
RAS pleura, which represents the onset of MMT. Afterwards, contact with the basal membrane and 
therefore also polarity of the cells is forfeited. This step during transition is often – as in our results – 
characterized by increased expression of α-SMA, a marker for active (myo-)fibroblasts 24. Another 
crucial factor for the progression of mesenchymal transitioning is remodeling of the ECM, with an 
important role for fibronectin 25. Although our in vitro data confirmed the increase in fibronectin in 
experimental conditions, our protein and mRNA results from pleura could not corroborate this. This 
might be explained by the fact that only pleural tissue - not parenchymal tissue - was sampled. Cells 
within the pleura are still undergoing transition and may therefore be unable to secrete fibronectin. 
Expression of Wt1 mRNA remained unchanged between groups. However, similar as for fibronectin, 
this is a late marker of MMT 26, explaining the lack of difference. The lack of a significant difference in 
some markers, although a clear trend is observed, could be due to the low number of analyzed samples 
as tissue availability remains scarce. 
As (alveolar) inflammation is considered a key player in CLAD 27, we wanted to assess the effect of 
inflammation on MMT by stimulating the pleural mesothelial cell line with interleukin (IL)-6 and IL-
1α, as these proteins were upregulated in BAL of RAS patients and were of prognostic importance 18. 
Cells exposed to both TGF-β1 and IL-1α showed a decrease in E-cadherin and increase in fibronectin 
expression. This suggests that IL-1α enhances TGF-β1-induced MMT, consistent with the hypothesis 
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that this alarmin is of considerable importance in the pathophysiology of CLAD 28, which could be an 
important area for further research.  
Given the current lack of treatment and the bad prognosis for RAS patients, there is a substantial 
need for new therapeutic approaches. TGF-β1 presents as an intuitive therapeutic target when attempting 
to prevent this process of MMT and consequently the progression of fibrosis, especially given its 
association with inflammation (figure 3). However, general antagonism of TGF-β1 would be unfavorable 
because of its beneficial roles 13. Other potential drugs may already be part of clinical practice and 
therefore, we examined a number of drugs that are currently in use to treat LTx patients such as 
azithromycin, montelukast, pirfenidone and steroids 29. Unfortunately, there were no differences in E-
cadherin or fibronectin expression between the different agents and TGF-β1-stimulated cells. However, 
as we did not assess any other changes – such as morphology, migration, etc. – we cannot state with 
certainty that these drugs do not affect or inhibit the MMT process. 
Admittedly, our study has several limitations. First, only 10 out of 19 RAS biopsies stained positive 
for calretinin, a marker of reactive mesothelial cells 12,26,30. The relatively low number of calretinin 
positive stainings is most likely due to the location where the biopsy is taken and the heterogeneity 
within the lungs as well as the possibility that even RAS itself is not homogeneous 31. Nevertheless, we 
were also able to show an increase of mesothelin, another marker of reactive mesothelial cells 17, in 
serum of RAS patients. A second limitation is the use of a cell line for our experiments.  Ideally, primary 
PMCs obtained from explanted lungs would have been used. However, this was challenging due to; (i) 
scarcity of organs available for isolation, (ii) concurrent infection, and (iii) fibroblast overgrowth. 
Although cell lines might not truly represent the patient, this allowed us to establish a controllable and 
reproducible in vitro MMT model. Thirdly, there is a great variation in n-values per experiment; 
however, this was dependent on availability of the required samples. Ideally, one patient cohort with 
each patient providing all three sample types would have been used. However, gathering these samples 
remains difficult due to rarity of the disease and the low incidence of (re-)transplantations/autopsies. 
Another limitation is the doses of TGF-β1 and drugs used to stimulate and treat the cells. A dose of 
10ng/mL TGF-β1 was used in our experiments, which is higher than the concentrations measured in 
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BAL. However, concentrations of proteins are known to be diluted in BAL and we believe that this dose 
might be physiologically relevant given the high abundance of TGF-β1 found in peripheral lung tissue 
on immunostainings. For the treatment experiments, we used concentrations based on literature and 
toxicity testing since the exact amount of drug that reaches the pleura is not known 32–34.  
Despite these limitations, we were able to implicate the pleura in the pathophysiology of restrictive 
allograft syndrome, via TGF-β1-induced mesothelial-to-mesenchymal transition. This is worth further 
investigation, especially to assess and develop possible pleural/TGF-β1-based treatment strategies. 
Moreover, given that mesothelial-to-mesenchymal transition is implicated in IPF, this suggests there 
may be at least a partial overlap in pathophysiological mechanisms. 
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FIGURES 
Figure 1 – TGF-β1 protein levels in broncho-alveolar lavage fluid of stable, BOS and RAS patients 
(A) TGF-β1 protein levels of stable (n=20), BOS (n=23) and RAS (n=26) patients, measured in BAL at 
CLAD diagnosis, presented as median ± IQR, showing increased levels in RAS compared to stable 
patients (p=0.024). (B) Kaplan-Meier survival curve showing a significant graft survival benefit for 
RAS patients with TGF-β1 levels lower than the median 14.5 pg/mL (black curve, p=0.033, HR 2.77, 
95% CI 1.1-7.1). Median survival was 0.49 years in group > median and 2.45 years in group < median. 
*p<0.05 
Figure 2 – Immunohistochemical patterns of TGF-β1 on RAS biopsies 
Representative RAS biopsies demonstrating three different TGF-β1 staining patterns: (A-C) 
represents pattern (i) with relatively low TGF-β1 expression, primarily subpleural staining and TGF-β1 
positivity in stromal cells and macrophages (4/19 or 21% of biopsies); (D) represents pattern (ii) with 
intermediate TGF-β1 expression and mainly subpleural and alveolar staining (9/19 or 47% of biopsies); 
(E) represents pattern (iii) with diffuse staining of the extracellular matrix (6/19 or 32% of biopsies). 
Liver (F) and tonsil (G) biopsies were used as positive controls to validate the TGF-β1 staining. TGF-β1 
positivity was found in Kupffer cells and histiocytes respectively. 
Figure 3 - Lymphocyte subpopulations in TGF-β1 expressing RAS biopsies 
Representative images of multiplex immunofluorescent stainings of RAS biopsies with low (A), 
intermediate (B) and high (C) TGF-β1 expression. Staining was performed for CD4 (red, T helper cells), 
CD8 (blue, cytotoxic T cells), CD20 (green, B cells) and CD68 (white, macrophages). The low TGF-β1 
group showed low degree of inflammation, with little and dispersed CD4, CD20 and CD68 positive 
staining. The intermediate TGF-β1 group showed low number of CD4, CD8, CD20 and CD68 positive 
cells. The high TGF-β1 group showed abundant CD4, CD8, CD20 and CD68 positive cells. 
Figure 4 – Relative fraction of pleura and attached infiltrates on CT in control, BOS and RAS lungs 
(A) shows the results of computed tomography (CT) scans of unused donor lungs, BOS and RAS lungs. 
Results are presented as mean ± SEM. A significant increase of volume percentage of pleura and 
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attached infiltrates in RAS compared to BOS (p=0.0003) and non-transplant control (p=0.025) lungs 
was observed (p=0.0004). (B) shows a representative CT scan of a slice from a RAS lung, while (C) 
also shows how pleura and attached infiltrates are highlighted (blue segmentation) to obtain results. N=8 
lungs in each group; * p<0.05; *** p<0.001 
Figure 5 – Calretinin staining of control, BOS and RAS explanted human lung biopsies 
(A) the proportion of biopsies with calretinin-positive stainings was significantly higher in RAS lungs 
(p=0.0001, n=19) compared to BOS (n=19) and non-transplant control (n=14) lungs. (B) shows 
representative calretinin stainings of BOS, non-transplant control, and RAS biopsies. Calretinin-positive 
cells were visible in normal pleura (arrowhead) as well as deeper within the subpleural fibrosis of the 
parenchyma (arrows) in RAS biopsies. Scale bars = 200 µm. (C) TGF-β1 staining severity showed a 
trend towards association with calretinin positivity. Biopsies with high TGF-β1 staining (i.e., diffuse 
staining of the extracellular matrix) were almost exclusively calretinin-positive (5/6 or 83% of biopsies, 
p=0.69), while in the low to intermediate TGF-β1 biopsies (i.e., subpleural and alveolar staining with 
TGF-β1 positivity in stromal cells and macrophages) only few were calretinin-positive (5/13 or 38% of 
biopsies). 
Figure 6 - Mesothelin protein levels in serum samples of stable, BOS and RAS patients 
Mesothelin protein levels measured in serum samples of stable (n=22), BOS (n=26) and RAS (n=28) 
patients. Results are presented as median ± IQR, showing increased levels in RAS compared to stable 
patients (p=0.0032). 
Figure 7 –Mesothelial-to-mesenchymal transition markers in pleural tissue 
MMT markers were assessed at mRNA and protein level in pleural tissue of non-transplant control, BOS 
and RAS lungs. E-cadherin (A-B), α-SMA (C-D), fibronectin (E-F), and Wt1 (G) were used as markers. 
Every dot represents the relative mean mRNA or protein amount of a single sample and horizontal lines 
represent median ± IQR per group. # 2 samples in the RAS group proved inadequate for protein 
extraction. * p<0.05; ** p<0.01 
